Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient therapeutic options for ...

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that ...

Enbumyst is the first and only intranasal loop diuretic approved in the U.S., offering a self-administered alternative ...

The U.S. regulator has signed off on Corstasis Therapeutics’ Enbumyst to relieve the edema associated with congestive heart ...

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, ...

The Food and Drug Administration (FDA) has approved Enbumyst ™, a nasal spray formulation of bumetanide, for the treatment of edema associated with congestive heart failure (CHF), and hepatic and ...

The FDA has approved Enbumyst (bumetanide nasal spray) for treating edema linked to congestive heart failure, liver disease, ...

Sequana Medical announces H1 2025 results and provides business update alfapump ® US commercialisation underway; Strengthened US reimbursement ...

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that its unidose liquid system is the delivery system for the recent US FDA-approved ...

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Unidose Liquid System is the delivery system for the recent U.S. FDA-ap ...

Medically reviewed by Jeffrey S. Lander, MD Key Takeaways ACE inhibitors and ARBs have little to no effect on cholesterol ...